



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**ASSESSMENT REPORT  
FOR  
Primeo HCT**

International Nonproprietary Name:

**aliskiren / hydrochlorothiazide**

**Procedure No. EMEA/H/C/002421**

Assessment Report as adopted by the CHMP with  
all information of a commercially confidential nature deleted.

Medicinal product no longer authorised



## Table of contents

<b>1. Background information on the procedure .....</b>	<b>3</b>
1.1. Submission of the dossier.....	3
1.2. Steps taken for the assessment of the product .....	4
<b>2. Scientific discussion .....</b>	<b>4</b>
3.1. Introduction .....	4
3.2. Quality aspects .....	5
3.3. Non-clinical aspects.....	5
3.4. Clinical aspects .....	5
3.5. Pharmacovigilance.....	5
3.6. Benefit-Risk assessment .....	6
3.7. Recommendation .....	6

Medicinal product no longer authorised

# 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Novartis Europharm Ltd. submitted on 2 December 2010 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Sprimeo HCT, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 23 September 2010.

The legal basis for this application refers to Article 10(c) of Directive 2001/83/EC, as amended – relating to informed consent from a marketing authorisation holder Novartis Europharm Ltd. for an authorised medicinal product Rasilez HCT (EU/1/08/491/001-080).

The application submitted is composed of administrative information, quality, non-clinical and clinical data with a letter from a MAH Novartis Europharm Ltd. allowing the cross reference to relevant quality, non-clinical and/or clinical data.

The applicant applied for the following indication:

“Treatment of essential hypertension in adults.

Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.”

### **Information on Paediatric requirements**

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/31/2009 for the following condition:

- Essential hypertension.

on the granting of a (product-specific) waiver for

- Essential hypertension.

### **Scientific Advice**

The applicant did not seek scientific advice at the CHMP.

## ***Licensing status***

The initial product Rasilez HCT was approved in the EU on 16 January 2009.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the Rapporteur's evaluation team were:

Rapporteur: **Daniela Melchiorri**      Co-Rapporteur: **János Borvendég**

### ***1.2. Steps taken for the assessment of the product***

- The application was received by the EMA on 2 December 2010.
- The procedure started on 19 December 2010.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 21 January 2011.
- During the meeting on 14-17 February 2011, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Sprimeo HCT on 17 February 2011. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 15 February 2011.

## **2. Scientific discussion**

### ***2.1. Introduction***

This marketing authorisation application for Sprimeo HCT (aliskiren/hydrochlorothiazide) has been submitted by Novartis Europharm Ltd as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

The MAH (Novartis Europharm Ltd) for Rasilez HCT, which was authorised on 16 January 2009 and submitted as a fixed combination application under Article 10(b) of Directive 2001/83/EC as amended, provided consent to make use of the pharmaceutical, non-clinical and clinical documentation of the initial dossier of this authorised product and any subsequent post-marketing procedures submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the Sprimeo HCT medicinal product are identical to the up-to-date quality, non-clinical and clinical profile of Rasilez HCT. The application for Sprimeo HCT concerns the identical strengths and pack sizes to those approved for Rasilez HCT and consists of only Module 1. Information on the scientific discussion can be found in the Rasilez HCT CHMP assessment reports and in the European Public Assessment Report (EPAR) published on the EMA website.

The approved indications are:

*“Treatment of essential hypertension in adults.*

*Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.*

*Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.”*

## **2.2. Quality aspects**

Since this application is an informed consent of the Rasilez HCT application, the quality data in support of the Sprimeo HCT application are identical to the up-to-date quality data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

## **2.3. Non-clinical aspects**

Since this application is an informed consent of the Rasilez HCT application, the non-clinical data in support of the Sprimeo HCT application are identical to the up-to-date non-clinical data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

An environmental Risk Assessment has been provided, which is identical to the version submitted as a follow-up measure for Rasilez HCT.

## **2.4. Clinical aspects**

Since this application is an informed consent of the Rasilez HCT application, the clinical data in support of the Sprimeo HCT application are identical to the up-to-date clinical data of the Rasilez HCT dossier, which have been assessed and approved (including all post-marketing procedures).

The Applicant has made appropriate commitments to update the product information for Sprimeo HCT post-authorisation in accordance with the outcome of ongoing regulatory procedures for Rasilez HCT.

## **User consultation**

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable for the following reasons:

In view of the fact that a readability test had been performed at the time of the original MAA for Rasilez HCT and the content of the package leaflet is identical to the latest approved leaflet of Rasilez HCT, no further testing is warranted.

## **2.5. Pharmacovigilance**

### **PSURs**

As requested by the Applicant and agreed by the CHMP, the PSUR cycle of this informed consent application will be aligned with the PSUR cycle for the reference product, Rasilez HCT, unless otherwise specified.

### **Detailed description of the pharmacovigilance system (DDPS)**

The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements.

### **Risk Management Plan**

The Applicant submitted a risk management plan (version 6) identical with that for Rasilez HCT. The Applicant has made a post-authorisation commitment to provide an updated RMP version based on the outcome of the ongoing assessments of the latest RMP for Rasilez HCT.

The CHMP, having considered the data submitted in the application, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information.

## **2.6. Benefit-Risk assessment**

This marketing authorisation application for Sprimeo HCT (aliskiren/hydrochlorothiazide) has been submitted by Novartis Europharm Ltd as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

The MAH (Novartis Europharm Ltd) for Rasilez HCT, which was authorised on 16 January 2009 and submitted as a fixed combination application under Article 10(b) of Directive 2001/83/EC as amended, provided consent to make use of the pharmaceutical, non-clinical and clinical documentation of the initial dossier of this authorised product and any subsequent post-marketing procedures submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the Sprimeo HCT medicinal product are identical to the up-to-date quality, non-clinical and clinical profile of Rasilez HCT. The application for Sprimeo HCT concerns the identical strengths and pack sizes to those approved for Rasilez HCT and consists of only Module 1. Information on the scientific discussion can be found in the Rasilez HCT CHMP assessment reports and in the European Public Assessment Report (EPAR) published on the EMA website.

Based on the assessment of all available data, the CHMP concluded that the benefit/risk balance is positive for the following proposed indications:

*“Treatment of essential hypertension in adults.*

*Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.*

*Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.”*

## **2.7. Recommendation**

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the benefit/risk balance of Sprimeo HCT in the treatment of essential hypertension was favourable and therefore recommended the granting of the marketing authorisation.